Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid plus bezafibrate versus bezafibrate alone in primary biliary cholangitis
NL-OMON59270Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of obeticholic acid and bezafibrate in primary biliary cholangitis (PBC) (2 arms), sponsored by Intercept Pharmaceuticals. Primary endpoint: Change in alkaline phosphatase. Started Jun 2021; status: completed.
02
Drugs
obeticholic acidbezafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON59270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59270.